Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Chemed (CHE)

Chemed Q3 revenue rises 7.4%, but 2024 EPS guidance revised to $23.00-$23.15

Mixed Impact 4 of 5 guidance Written later

Chemed reported third-quarter 2024 revenue of $606.2 million, up 7.4%, and adjusted diluted EPS of $5.64, up 6.0%. The company said Roto-Rooter's revenue and adjusted EBITDA were softer than anticipated, and it revised full-year 2024 adjusted EPS guidance to $23.00 to $23.15, which implies a 13.3% to 14.0% increase over 2023's $20.30.

Key points

  • Q3 2024 revenue $606.2 million, up 7.4%; GAAP diluted EPS $5.00, up 1.4%; adjusted diluted EPS $5.64, up 6.0%
  • VITAS net patient revenue $391.4 million, up 17.3%; Roto-Rooter revenue $214.8 million, down 6.9%
  • Roto-Rooter adjusted EBITDA $56.4 million, down 15.8%; adjusted EBITDA margin 26.3%, down 275 basis points
  • Full-year 2024 adjusted EPS guidance $23.00 to $23.15; company repurchased 100,000 shares for $57.8 million in the quarter

The filing

CompanyChemed (CHE)
Form8-K, current report
Filed with the SECOct 29, 2024, 4:30 PM ET
Accession number0001562762-24-000241

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.